|
Valoración de DCF de Mersana Therapeutics, Inc. (MRSN)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Mersana Therapeutics, Inc. (MRSN) Bundle
¿Busca evaluar el valor intrínseco de Mersana Therapeutics, Inc.? Nuestra calculadora DCF (MRSN) integra datos del mundo real con características integrales de personalización, lo que le permite refinar los pronósticos y mejorar sus estrategias de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.1 | .8 | .0 | 26.6 | 36.9 | 31.9 | 27.5 | 23.8 | 20.6 | 17.8 |
| Revenue Growth, % | 0 | -98.03 | -94.81 | 61716.28 | 38.65 | -13.55 | -13.55 | -13.55 | -13.55 | -13.55 |
| EBITDA | -26.7 | -86.7 | -167.9 | -200.0 | -166.1 | -29.5 | -25.5 | -22.1 | -19.1 | -16.5 |
| EBITDA, % | -63.45 | -10468.12 | -390553.49 | -752.26 | -450.63 | -92.69 | -92.69 | -92.69 | -92.69 | -92.69 |
| Depreciation | 1.2 | 1.0 | .9 | .9 | 1.5 | 13.4 | 11.6 | 10.0 | 8.7 | 7.5 |
| Depreciation, % | 2.96 | 121.98 | 1988.37 | 3.49 | 4.12 | 42.11 | 42.11 | 42.11 | 42.11 | 42.11 |
| EBIT | -28.0 | -87.7 | -168.8 | -200.9 | -167.6 | -29.7 | -25.7 | -22.2 | -19.2 | -16.6 |
| EBIT, % | -66.41 | -10590.1 | -392541.86 | -755.74 | -454.75 | -93.28 | -93.28 | -93.28 | -93.28 | -93.28 |
| Total Cash | 99.8 | 255.1 | 177.9 | 280.7 | 209.1 | 31.9 | 27.5 | 23.8 | 20.6 | 17.8 |
| Total Cash, percent | .0 | .0 | .4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 30.0 | .0 | 6.4 | 5.5 | 4.8 | 4.1 | 3.6 |
| Account Receivables, % | 0 | 0 | 0 | 112.86 | 0 | 20 | 20 | 20 | 20 | 20 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 7.3 | 8.3 | 12.3 | 14.0 | 7.3 | 18.5 | 16.0 | 13.8 | 11.9 | 10.3 |
| Accounts Payable, % | 17.32 | 1007.25 | 28653.49 | 52.48 | 19.86 | 57.93 | 57.93 | 57.93 | 57.93 | 57.93 |
| Capital Expenditure | -.6 | -.5 | -.6 | -2.2 | -2.2 | -11.0 | -9.5 | -8.2 | -7.1 | -6.1 |
| Capital Expenditure, % | -1.44 | -57.13 | -1506.98 | -8.27 | -5.88 | -34.54 | -34.54 | -34.54 | -34.54 | -34.54 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -27.0 | -88.0 | -167.9 | -204.2 | -167.6 | -29.5 | -25.5 | -22.0 | -19.0 | -16.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -19.0 | -86.5 | -163.8 | -233.8 | -144.9 | -22.3 | -25.0 | -21.6 | -18.7 | -16.2 |
| WACC, % | 10.91 | 11.07 | 11.04 | 11.07 | 11.07 | 11.03 | 11.03 | 11.03 | 11.03 | 11.03 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -78.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -17 | |||||||||
| Terminal Value | -183 | |||||||||
| Present Terminal Value | -108 | |||||||||
| Enterprise Value | -186 | |||||||||
| Net Debt | -141 | |||||||||
| Equity Value | -46 | |||||||||
| Diluted Shares Outstanding, MM | 116 | |||||||||
| Equity Value Per Share | -0.39 |
What You Will Get
- Real MRSN Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Mersana Therapeutics' future performance.
- User-Friendly Design: Designed for professionals but easy for beginners to navigate.
Key Features
- 🔍 Real-Life MRSN Financials: Pre-filled historical and projected data for Mersana Therapeutics, Inc. (MRSN).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Mersana’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Mersana’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Mersana Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Mersana Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Mersana Therapeutics, Inc. (MRSN)?
- Accurate Data: Utilize real Mersana financials for dependable valuation outcomes.
- Customizable: Tailor essential inputs such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations mean you won’t have to start from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Clear layout and step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing Mersana Therapeutics, Inc. (MRSN) stocks.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Equip clients with precise valuation insights for Mersana Therapeutics, Inc. (MRSN).
- Students and Educators: Utilize real-world data to practice and teach financial modeling techniques.
- Biotech Enthusiasts: Gain insights into how biotech companies like Mersana Therapeutics, Inc. (MRSN) are valued in the market.
What the Template Contains
- Pre-Filled DCF Model: Mersana Therapeutics, Inc.'s (MRSN) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Mersana's profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.